TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04968327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Description: MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional canine retraction
Description: using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional canine retraction
Description: using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
Study: NCT04527458

Intervention type: OTHER
Intervention: Patient Characteristics
Description: Characteristics of the patients

Intervention type: OTHER
Intervention: Patient Characteristics
Description: Characteristics of the patients

Intervention type: OTHER
Intervention: COVID-19 treatments
Description: Specific treatments used on COVID-19 patients

Intervention type: OTHER
Intervention: COVID-19 treatments
Description: Specific treatments used on COVID-19 patients

Intervention type: OTHER
Intervention: Differences in triage
Description: Triage criteria for treating COVID-19 patients

Intervention type: OTHER
Intervention: Differences in triage
Description: Triage criteria for treating COVID-19 patients

Intervention type: OTHER
Intervention: Surge capacity
Description: Capacity of hospitals

Intervention type: OTHER
Intervention: Surge capacity
Description: Capacity of hospitals
Study: NCT04579458

Intervention type: PROCEDURE
Intervention: Collection of tears and saliva.
Description: Saliva and ocular tears will be collected.
Study: NCT00505765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-108
Description: AL-108, 5 mg/day- one spray in each nostril once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-108
Description: AL-108, 30 mg/day- 3 sprays in each nostril, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- 3 sprays in each nostril, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- one spray in each nostril, once per day
Study: NCT00683852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 5mg
Description: Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 2mg
Description: For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 2mg
Description: For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
Study: NCT02921594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard XP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard XP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard CR

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard CR
Study: NCT00561795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034)
Description: 800 mg orally once a day for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034)
Description: 800 mg orally once a day for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV over one hour every 3 weeks of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV over one hour every 3 weeks of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
Study: NCT03396172

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeDom
Description: Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
Study: NCT01768182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
Study: NCT02655497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial education
Study: NCT01743820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg Primaquine
Study: NCT00670449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod was supplied in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod was supplied in capsules.
Study: NCT01743820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Primaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg Primaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0625 mg/kg Primaquine
Study: NCT01058694

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
Study: NCT00003512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00582998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Dressing
Description: Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure Device
Description: Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
Study: NCT00196144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized Programming of PVAB
Description: Performance of a test to detect far-field R-wave sensing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nominal PVAB
Description: nominal pacemaker settings
Study: NCT03269058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg daily per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg daily per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo of Dapagliflozin per day per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo of Dapagliflozin per day per os
Study: NCT03276546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shared decision-making tool (SHARE-D)
Description: questionnaire
Study: NCT04357808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single dose treatment with sarilumab 2 x 200 mg subcutaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standar of care
Description: Usual clinical care
Study: NCT02792153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
Study: NCT00038233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
Study: NCT02348710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise OE workbook
Description: The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet workbook
Description: The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
Study: NCT00933465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide Hydrochloride) syrup
Description: syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide Hydrochloride) syrup
Description: syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide hydrochloride) tablets
Description: tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imodium (Loperamide hydrochloride) tablets
Description: tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most
Study: NCT02478164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Study: NCT03981081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
Study: NCT03046199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordination
Description: Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordination
Description: Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
Study: NCT01388075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: oral, 450 mg/day , 7 days
Study: NCT04592965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical and neuropsychological assessments
Description: The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of PH and associated bodily states
Description: Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting-state fMRI acquisition
Description: Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction of PH and associated bodily states (MRI)
Description: Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
Study: NCT04471753

Intervention type: BEHAVIORAL
Intervention: Coma Recovery Scale-Revised
Description: Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
Study: NCT04298996

Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine oxidative stress markers TAS and TOS

Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine oxidative stress markers TAS and TOS
Study: NCT01058694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
Study: NCT01230489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MediHoney
Description: In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
Study: NCT00355251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/Atorvastatin 80 mg
Description: Atorvastatin 40 mg/80 mg
Study: NCT03629405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C - pH 4 Cosmetic Product WO 3741
Description: Application of the product on the pre-defined skin area on the forearms twice daily for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D - pH 5.8 Cosmetic Product WO 4081-1
Description: Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
Study: NCT03802331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495,
Description: single oral doses
Study: NCT04442464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral Lens
Description: 15.0 mm diagnostic spherical rigid contact lens
Study: NCT04394039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public space exposure
Description: landscapes with nature and/or classified as contemplative (through a CLM psychometric measure) are expected to elicit different brainwave oscillations as compared to noncontemplative ones.
Study: NCT03215199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NAPT
Description: Web-based depression and distress monitoring application
Study: NCT02138903

Intervention type: OTHER
Intervention: trans thoracic echocardiography

Intervention type: OTHER
Intervention: trans thoracic echocardiography
Study: NCT01016327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-1116354
Description: Oral daily administration for 7 consecutive days every 14 days
Study: NCT01331993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
Study: NCT02942485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: P/r suppositories

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: P/o tablets
Study: NCT00687674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg orally Days 1, 8, 15, 22 of 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM \& 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
Study: NCT00663754

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dissonance-based eating disorder prevention program
Description: Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
Study: NCT01331993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (AstraZeneca)
Description: VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIMOVO (Patheon)
Description: VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
Study: NCT01092325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL-1020
Description: Intravenous infusion of one of 3 active dosages of CXL-1020